⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVS News
Novartis AG
Next-Generation Biologics and Biosimilars Market to Hit 251.13 billion Dollars by 2033 - Strategic Revenue Insights (SRI)
prnewswire.com
AMGN
PFE
RHHBY
NVS
MRK
LLY
Cystic Fibrosis Therapeutics Market Set to Reach USD 35.09 Billion by 2033 as Precision CFTR Modulator Therapies Transform Patient Outcomes
prnewswire.com
VRTX
RHHBY
NVS
TEVA
GILD
CAR T-Cell Therapy for the Multiple Myeloma Market, 2025-2035: Extensive Data on Products, End Users, Regions and Companies - ResearchAndMarkets.com
businesswire.com
BMY
JNJ
NVS
GILD
Orphan Drugs Market to Surge to USD 486.51 Billion by 2032 as Rare Disease Innovation, Gene Therapies & Precision Medicine Reshape Global Healthcare
prnewswire.com
JNJ
ABBV
VRTX
AZN
INCY
BIIB
NVS
ROG
PFE
BMY
Antitumor ADC Drugs Market Forecast Shows Strong 12.86% CAGR Through 2035
globenewswire.com
PFE
AZN
DSNKY
GILD
IMMU
REGN
BIIB
BMY
MRK
NVS
AMGN
LLY
JNJ
ABBV
BNTX
SEGN
RHHBY
Takeda
IQV
PE
Interleukin-6 (IL-6) Receptor Antagonists and IL6- Inhibitors Competitive Intelligence Report 2025: Launch of the First Tocilizumab Biosimilar Antibodies Highlights the Attractiveness of the Market
globenewswire.com
NVS
Hidradenitis Suppurativa Market Opportunity Forecast Report 2025: 7MM Market to Reach $7.8 Billion by 2034, Driven by New Biologics and Small-Molecule Launches Including Sonelokimab and Povorcitinib
globenewswire.com
ABBV
INCY
JNJ
MRK
NVS
SNY
Cure SMA Welcomes Broad FDA Approval of Itvisma™ for Spinal Muscular Atrophy, Reinforces Commitment to Patient Access and Support
prnewswire.com
NVS
Comprehensive Psoriasis Industry Assessment 2025-2035 - Asia-Pacific Real-World Evidence Reveals Strengthened and Effective Healthcare Strategies
globenewswire.com
ABBV
AMGN
NVS
JNJ
LLY
DNA Damaging Agents Market Grows at 11.67% CAGR, to Hit USD 46.31 Billion by 2034
globenewswire.com
XRAY
NVS
RUC
NIRA
TLZ
AZN
BMY
MRK